Menu
2026 Session

Budget Amendments - HB30 (Committee Approved)

View Budget Item
View Budget Item amendments

Modify Medicaid Criteria for Weight Loss Drugs (language only)

Item 291 #9h

Item 291 #9h

Health and Human Resources
Department of Medical Assistance Services

Language

Page 365, line 11, strike "no longer" and insert "only".

Page 365, line 12, after "weight loss", strike "except".

Page 365, line 13, after "greater than", insert "or equal to".

Page 365, line 14, after "greater than", insert "or equal to".

Page 365, line 15, after "greater than", insert "or equal to".

Page 365, line 15, after "pre-diabetes" strike "or" and insert ",".

Page 365, line 16, after "disease" insert ", or obstructive sleep apnea".

Page 365, line 17, strike ", excluding Glucagon-like peptide-1 drugs and".

Page 365, line 18, strike "any other newer weight loss medications".

Page 365, line 26, after "changes, as needed, to", insert:

"and/or managed care contract changes, as needed, to pursue and".

Page 365, line 26, after "use of", insert "(i)".

Page 365, line 27, "after medications,", insert:

"or (ii) any rebate or value-based purchasing agreement negotiated directly between the federal government and a manufacturer of GSP-1 receptor agonist medications".

Page 365, line 28, after "price", insert:

"to the Commonwealth".

Page 365. strike lines 30 through 32, and insert:

"4. DMAS shall not list on the Common Core Formulary, any drug in the Common Core Formulary class which contains GLP-1 receptor agonist medications, for any indication described in paragraph MMMM 2, if the net price for a one-month supply exceeds $245 through the best agreement available to the state."



Explanation

(This amendment modifies language in the introduced budget regarding the coverage of weight loss medications in the Medicaid program. The amendment requires the Department of Medical Assistance Services (DMAS) to amend the state plan for medical assistance and regulations to cover weight loss drugs in certain circumstances. It clarifies coverage for individuals with a body mass index greater than or equal to the percentages listed among the criteria and adds criteria for coverage when an individual has a BMI greater than or equal to 27 and has obstructive sleep apnea. It removes unnecessary language excluding GLP-1 medications and newer weight loss drugs, from criteria allowing coverage for traditional weight loss drugs. It provides DMAS with authority to make managed care contract changes and pursue any rebate or value-based purchasing agreement negotiated between the federal government and a manufacturer of GLP-1 receptor agonist medications if the net price to the Commonwealth is lower than that obtained under an existing rebate agreement. Finally, it clarifies that DMAS is prohibited from listing a GLP-1 medication on the Common Core Formulary for weight loss if the net price for a one-month supply exceeds $245.)